prospective, data collection of consecutive, unselected patients presenting with STEMI. Among these 11,530 STEMI patients, 496 (4.3%) were resuscitated from cardiac arrest. The cohort for their reported observational study included 272 patients who manifested cardiogenic shock after being resuscitated. Most of these patients (174) were found to have multivessel coronary artery disease. Among the patients with multivessel disease, 2 revascularization approaches were compared: culprit-only or multivessel primary percutaneous coronary intervention (PCI). Survival at 6 months was significantly greater in patients undergoing multivessel PCI than in those treated with culprit vessel PCI only (43.9% vs. 20.4%; p Ͻ 0.002).
Though obviously not a prospective, blinded, or randomized trial, these results are consistent with the growing database of cohort studies showing remarkable outcome improvements with more aggressive post-resuscitation care.
Sunde et al. (5) were the first to report their experience with more aggressive post-resuscitation care improving long-term survival after cardiac arrest. They doubled their historical survival to discharge with favorable neurological outcome rate from 26% to 56%. The most important post-cardiac arrest treatments were therapeutic hypothermia and early coronary angiography. The literature now reports the outcomes of over 1,500 cardiac arrest patients so treated after successful resuscitation (6) . This worldwide experience shows that aggressive post-resuscitation care is achievable, safe, and beneficial in those suffering cardiac arrest in the context of STEMI (2,7-10), non-STEMI (11) (12) (13) , and now STEMI with associated cardiogenic shock (4). Not only was 6-month survival better with full revascularization by multivessel PCI, but remarkably 90% of those who survived had favorable neurological recovery (4).
Mylotte et al. achieved remarkable outcomes in this, the very highest risk subgroup of all STEMI patients (4). Maynard et al. (14) from Seattle showed the high risk associated with such patients using a mortality model based on the nearly 16,000 consecutive PCI in Washington state. The overall mortality rate was 1%, whereas the mortality rate in post-resuscitated patients was 19%. Interestingly, in their analysis, compared with post-resuscitation status, only cardiogenic shock had a higher OR for predicting death post-PCI. Manifesting cardiogenic shock after resuscitation from cardiac arrest combines these 2 highest-risk conditions for death after STEMI.
Mylotte et al. (4) publish the first data substantiating the concept that a complete revascularization, as opposed to a culprit-only strategy in those with cardiogenic shock, can improve outcome. Though such a strategy has been espoused previously, this is the first clinical evidence of efficacy for this approach. Perhaps they were successful in showing such an improvement because of the very high-risk population studied. From the Division of Cardiology, University of Arizona, Sarver Heart Center, Tucson, Arizona. Dr. Kern has received honoraria as a consultant for Zoll Medical and PhysioControl.
Calculating the observed-to-expected ratio for death from their recent experience in treating those with STEMI complicated by cardiac arrest and then cardiogenic shock is revealing (4) . According to their earlier report, the expected mortality in such patients is 67%. These investigators from Paris found that multivessel PCI performed immediately upon arrival at the hospital improved outcome, lowering the mortality rate to 56%, thereby achieving an observed-toexpected ratio of 0.84 (p Ͻ 0.03). This approach works in these very sick patients! Once again these pioneers from Paris are leading the way. They have reset the bar in treating the "sickest of the sick" among cardiac patients. Hopefully, such therapy can be extended to all post-cardiac arrest patients, not just in Paris, but in other communities as well. This will likely only occur when we recognize the importance of complete, emergency revascularization in this very sick subgroup of STEMI patients.
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